Spanish pharmaceutical companies listed on the continuous market close the third quarter of 2021 in the red. The aggregate capitalization of Grifols, Almirall, Rovi, Faes Farma, Pharma Mar, and Reig Jofre fell by 5.8% between June and September.
The performance of the pharmaceutical sector in the third quarter was worse than that of the Ibex35, the Spanish benchmark index, which fell by 0.3% in the same period. The six listed pharmaceutical companies closed the third quarter with a stock market value of $20 billion (€17.3 billion), compared to $21.3 billion (€18.4 billion) at the end of the previous quarter. This decline occurred in all companies except for Faes Farma, whose shares rose by a slight 0.6%.
Read more on the subject and find other important financial news with our companion app Born2Invest.
The six listed pharmaceutical companies closed the third quarter with a stock market value of $20 billion (€17.3 billion)
The biggest fall was for Reig Jofre. The pharmaceutical company’s shares corrected by 8.45% in the period, to $5.2 (€4.5) per share. The company closed the first half of 2021 with a profit of $4 million (€3.5 million), which translates into a 7.7% drop compared to the same period in 2020, according to the latest available data.
The second-largest decline was recorded by Grifols. The Catalan pharmaceutical company’s shares fell by 7.5% to $24.4 (€21.08). Nevertheless, Grifols continues to be the pharmaceutical company with the largest capitalization, with more than $10.3 billion (€8.9 billion).
A few days ago, the company specialized in the production of plasma derivatives began the process for the issue of senior unsecured bonds for $2.3 billion (€2 billion) with a maturity date of 2028 to finance the purchase of the German company Biotest. This acquisition has increased its indebtedness more than five times and has caused S&P Ratings to downgrade its credit rating to BB- from the previous BB.
Almirall closed the third quarter in the stock market with a 6.7% drop, to $15.9 (€13.7) per share
Grifols is followed by Almirall. The pharmaceutical company, owned by the Gallardo family, which last May increased its share capital by more than $347,000 (€300,000), closed the third quarter on the stock exchange with a 6.7% drop, to $15.9 (€13.7)per share.
The Catalan pharmaceutical company recorded a loss of $49.6 million (€42.8 million) in the first half of the year, compared to a profit of $49 million (€42.4 million) in the same period of 2020.
Rovi and Pharma Mar also fell on the stock market. The shares of the former fell to $65.4 (€56.5) per share at the end of the third quarter, compared to $67.6 (€58.4) in the second quarter. The shares of the Galician company stood at $86 (€74.4) per share, down 1.8% compared to the previous quarter.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Boiron Enters the Medical Cannabis Business
Boiron is counting on cannabis to restore his health. The change was announced on the BFM Business TV channel. It's...
Tech Innovation Is about to Takeoff: Get Ready for It with XRApplied
While most of us grew up bearing witness to a tremendous pace of tech advancements, things seem to have stagnated...
Glen Invest, the Moroccan Investment Company Set Up in Casablanca
Glen Invest's priorities for the region are clear. They concern investments in the processing industry for mass consumer goods, "with...
Why Are Syncrude, Ledcor Group, and Ekati Mines So Excited about Triad Pro Innovators’ New EEL Diesel Hybrid Genset?
It's understandable if the words ‘diesel hybrid genset' don’t get your heart racing. But what if we throw in an...
New Strategy, New Brand: The Secret Re-Start of Exporo
According to information of Finanz-Szene.de, the strategy turn and the internal reorganization are also a consequence of difficulties, which Exporo...
Crypto2 weeks ago
Satispay and Young Platform Team Up to Simplify Cryptocurrency Purchases
Biotech2 weeks ago
Rethinking DMT: Algernon Pharmaceuticals’ Novel Approach to Stroke Treatment
Business2 weeks ago
Before the Metaverse: Augmented Reality in Education
Featured2 weeks ago
Why Soybeans and Soybean Oil Closed Lower